Efficacy and safety of 'fixed dose' versus 'loose' drug regimens for treatment of pulmonary tuberculosis in two high TB-burden african countries: A randomized controlled trial

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Aseffa, Abraham ^a   Chukwu, Joseph N ^b   Vahedi, Mahnaz ^c   Aguwa, Emmanuel N ^d   Bedru, Ahmed ^a   Mebrahtu, Tesfamariam ^a   Ezechi, Oliver C ^e   Yimer, Getnet ^f   Yamuah, Lawrence K ^a   Medhin, Girmay ^g   Connolly, Cathy ^h   Rida, Wasima ⁱ   Aderaye, Getachew ^g   Zumla, Alimuddin I ^j   Onyebujoh, Philip C ^c   Yamuah, Lawrence ^k   Akalu, Zenebe ^k   Lema, Teklu ^k   Mitike, Getnet ^k   Goshu, Solomon ^k   Feleke, Beniam ^k   Tadesse, Zerihun ^k   Chukuwu, Joseph ^k   Egbuka, Sylvester ^k   Azogu, Ben ^k   Eze, Emmanuel ^k   Elom, Lawrence ^k   Ajoku, Osita ^k   Okafor, Oge ^k   Ugwo, Chioma ^k   more..

^a ARMAUER HANSEN RESEARCH INSTITUTE   (Ethiopia)

^b Klinikum der Ludwig Maximilians Universität München   (Nigeria)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF NIGERIA   (Nigeria)

^e NIGERIAN INSTITUTE OF MEDICAL RESEARCH   (Nigeria)

^f ADDIS ABABA UNIVERSITY   (Ethiopia)

^g ADDIS ABABA UNIVERSITY   (Ethiopia)

^h SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

ⁱ Biostatistics Consultant   (United States)

^j UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BACTERIUM CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; AFRICA; AGED; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADULT; AFRICA; AGED; ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84977545132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157434     Document Type: Article

References (22)

1. WHO Annual Global TB Report 2014. Available: http://www.who.int/tb/publications/global-report/en/. Accessed 23 October 2015.
2. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2(1):10-5. PMID: 9562106
3. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013; 13(6):529-39. doi: 10.1016/S1473-3099(13)70030-6 PMID: 23531391
4. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8):713-9. PMID: 17679131
5. WHO/TDR. Informal consultation on 4-drug fixed-dose combinations (4FDCs) compliant with the WHO Model List of essential drugs. 2001. (TDR/TB/4FDC/02.1.WHO/CDS/TB/2002.299).
6. International Union Against Tuberculosis and Lung Disease/World Health Organization. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. Int J Tuberc Lung Dis 1999; 3(11 Suppl 3):S282-3. PMID: 10593704
7. Albanna AS, Smith B, Cowan D, Menzies D. Fixed Dose Combination anti-tuberculosis therapy: a systematic review and meta-analysis. ERJ Express. Published on January 11, 2013 as doi: 10.1183/09031936.00180612
8. World Health Organization (WHO). Treatment of tuberculosis: guidelines for national programmes- 4th ed. (WHO/HTM/TB/2009.420). Available: http://www.who.int/tb/publications/tb-treatmentguidelines/en/index.html, Accessed 2 August 2014.
9. American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52 (RR-11): 1-77. PMID: 12836625
10. International Standards for Tuberculosis Care (ISTC). 2nd ed. The Hague, Tuberculosis Coalition for Technical Assistance, 2009. Available: http://www.who.int/tb/publications/2006/istc-report.pdf. Accessed 2 August 2013.
11. Agresti A, Caffo B. Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures. Am Stat 2000; 54(4):280-288.
12. Lienhardt C, Cook SV, Burgos M, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 2011, 305(14):1415-23. doi: 10.1001/jama.2011.436 PMID: 21486974
13. Bartacek A, Schutt D, Panosch B, Borek M, et al. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 2009; 13(6):760-6. PMID: 19460254
14. Mathew JL. Fixed dose drug combination for treatment of tuberculosis. Indian J Pediatrics 2009; 46(10):877-80.
15. Blomberg B, and Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs 2003; 63(6):535-53. PMID: 12656652
16. Chaulet P. Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities. Int J Tuberc Lung Dis 1999; 3(11 Suppl 3):S353-S357; discussion S381-S387. PMID: 10593717
17. Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA, et al. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis (Edinb) 2003; 83(1-3):183-6.
18. Su WJ, Perng RP. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis 2002; 6(11):1029-32. PMID: 12475151
19. Panchagnula R, Agrawal S, Ashokraj Y, Varma M, Sateesh K, Bhardwaj V, et al. Fixed dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol 2004; 26(9):70321.
20. Ellard GA, Fourie PB. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis 1999; 3(11 Suppl 3):S3018; discussion S317-21.
21. McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C, et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother 2012; 56(6):3232-8. doi: 10.1128/AAC.05526-11 PMID: 22411614